In the future, as the Centre builds capacity and grows we will begin offering treatment as regulations allow, which will include:

  • MDMA-assisted psychotherapy for Posttraumatic Stress Disorder (PTSD), in collaboration with the Multidisciplinary Association for Psychedelic Studies (MAPS)
  • Psilocybin-assisted psychotherapy for end-of-life distress
  • Psilocybin-assisted psychotherapy for treatment-resistant depression

The Centre's faculty will also begin collecting safety and quality improvement data to inform future clinical programming. An early priority will be to treat vulnerable populations who are historically underrepresented in clinical trials, including refugees, members from BIPOC and LGBTQ+ communities and individuals from low socioeconomic backgrounds. The Centre will also recruit therapists from these communities to participate in its training program.

To make a donation to support the Nikean Psychedelic Psychotherapy Research Centre, please visit the UHN Foundation.